Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Thursday's Featured News
A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?Written by Jeffrey Neal Johnson. First Published: 4/7/2026. 
Key Points
- Abbott's Medical Devices division continues to accelerate, demonstrating the underlying strength within the company's largest business segment.
- Abbott's impressive history of consecutive dividend increases underscores its commitment to consistently rewarding long-term shareholders.
- Strategic acquisitions are positioning Abbott to lead in new high-growth healthcare sectors, securing a powerful pipeline for future expansion.
- Special Report: Elon’s “Hidden” Company
In the world of investing, stability is a prized commodity. Few companies embody that stability better than Abbott Laboratories (NYSE: ABT), a diversified healthcare powerhouse and a member of the elite dividend kings. For decades, investors have relied on Abbott for steady growth and dependable income. That long-standing reputation makes its recent performance all the more striking.
Bill Spetrino, editor of The Dividend Machine, started with just an $8,000 IRA and invested it in a single dividend stock he calls the World's Greatest Dividend Stock - and he's sharing a free report that names it.
Spetrino has identified what he calls The Great American Turnaround, an economic shift driven by three catalysts he believes will reward dividend-focused investors who position early. His free bulletin outlines why waiting for markets to settle could mean paying more for the same yields. Read the free bulletin now and discover the dividend stocks to watch
Abbott Laboratories’ stock price recently touched its 52-week low, closing just above $100 in the final trading days of March. This sharp downturn has left many wondering whether the foundation of this industry leader is cracking. A deeper look into Abbott Laboratories’s current situation reveals a potential disconnect between market sentiment and operational reality, raising a critical question: Is the market’s pessimism justified, or has a significant value opportunity emerged for long-term investors? Separating the Signal From the NoiseA stock like Abbott doesn't fall without reason, and its recent decline stems from two distinct pressures. The first is an internal headwind from its Nutrition segment. Abbott Laboratories’ fourth-quarter 2025 earnings report showed a 9.1% organic sales decline in this division. This decline was primarily due to market-share losses in its U.S. pediatric business and pricing dynamics that constrained volume. Management has been transparent about the challenge and outlined a clear turnaround plan. CEO Robert B. Ford described price and promotion initiatives and a pipeline of at least eight new product launches in 2026 to reignite volume growth, forecasting a return to growth in the second half of the year. The second factor is external and broader in scope. The market has been rotating capital away from defensive sectors like the healthcare sector into higher-beta areas such as artificial intelligence (AI) and the energy sector in search of faster returns. This rotation has weighed on many fundamentally sound healthcare names, including Abbott, depressing their share prices for reasons largely unrelated to company-specific performance or long-term prospects. Abbott’s Engine Room Is Running StrongWhile the Nutrition segment navigates a short-term recovery, Abbott Laboratories' core remains exceptionally strong, powered by its largest and most profitable division: Medical Devices. That segment is accelerating, posting 10.4% organic growth in the most recent quarter. Abbott's diversified model provides a powerful counterbalance to the isolated weakness in Nutrition, and the company's overall health is most evident in these high-performing areas.
Medical Devices: The Medical Devices business is firing on multiple cylinders, driven by market-leading innovation in critical care areas. Diabetes Care: The FreeStyle Libre franchise of continuous glucose monitors (CGM) remains a growth phenomenon. This product line, which lets users track glucose levels without routine fingersticks, generated more than $7.5 billion in sales in 2025 and is a primary driver of Abbott’s sustained success. Cardiovascular Leadership: Abbott is a dominant force in cardiovascular health. Its Electrophysiology business grew at a double-digit rate, while Structural Heart posted strong organic growth of 8.7%. This momentum comes from a portfolio of best-in-class products, such as MitraClip and TriClip, which offer minimally invasive valve-repair solutions, and a pipeline of innovations, including the FDA-approved Volt PFA System for treating atrial fibrillation. Abbott is also making a major strategic move to secure future growth through the acquisition of Exact Sciences. Exact Sciences is a leader in cancer screening and diagnostics, best known for its non-invasive colon cancer test, Cologuard. The deal would position Abbott as a leader in the rapidly expanding cancer-diagnostics market, adding a new, high-growth vertical with multi-billion-dollar potential and the ability to contribute meaningfully to revenue over the coming years. This bullish outlook is shared by professional analysts. Wall Street maintains a Moderate Buy consensus rating on the stock. The average 12-month price target is $135.47, implying potential upside of more than 30% from current levels and signaling that many analysts view the shares as undervalued. A Bedrock of Reliability for Income InvestorsFor long-term investors focused on reliable income, Abbott’s dividend is especially compelling. Abbott Laboratories is a member of the S&P 500 Dividend Kings, an exclusive group of companies that have increased their dividend for at least 50 consecutive years. That record demonstrates a deep-seated commitment to returning capital to shareholders through all market cycles. The recent decline in Abbott’s stock price has a direct, positive effect for new investors: a higher dividend yield. At current prices, Abbott yields roughly 2.5%, allowing investors to lock in a higher rate of income from a historically reliable payer. The dividend payout ratio is about 68% of earnings, and the dividend represents roughly 37% of cash flow, indicating Abbott generates more than enough cash to cover payments with room for future increases. A Disconnect Between Price and ValueCurrent market sentiment around Abbott appears disconnected from the business reality. Temporary headwinds in one division and a sector-wide capital rotation have depressed the stock price, even as Abbott's fundamental growth engines accelerate. Its dominant Medical Devices division continues to deliver strong results, the dividend remains a bedrock of reliability, and catalysts like the Exact Sciences acquisition could add significant new growth. For investors with a long-term perspective, the current valuation suggests a notable gap between market price and fundamental value—an opportunity worth considering. |
